Mark Kaye Power - 02 Jun 2025 Form 4 Insider Report for CONMED Corp (CNMD)

Reporting relationship: Director
Issuer ticker: CNMD
Reported as of: 02 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Jun 2025, 17:41:24 UTC
Prior SEC filing: 25 Apr 2025
Next SEC filing: 03 Oct 2025
Source filing: View source filing
Reporting owner signature: /s/ Thomas Fistek for Mark Kaye by Power of Attorney

Key filing fact

Mark Kaye Power filed Form 4 for CONMED Corp (CNMD) on 04 Jun 2025.

Key facts

This page summarizes Mark Kaye Power's Form 4 filing for CONMED Corp (CNMD).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 04 Jun 2025, 17:41.

Change

Previous filing in this sequence was filed on 25 Apr 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001748691 Primary reporting owner

Kaye Mark

Relationship: Director
Address: C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO
Signature: /s/ Thomas Fistek for Mark Kaye by Power of Attorney
Signature date: 04 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CNMD transaction Derivative

Options To Purchase Common Stock

Award

Transaction value: $0
Shares: +8,061
Change %
Price: $0.000000
Shares after: 8,061
Date: 02 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,061
Exercise price: $55.38
Footnotes: F1

CNMD transaction Derivative

RSUs (Restricted Stock Units)

Award

Transaction value: $0
Shares: +668
Change %
Price: $0.000000
Shares after: 668
Date: 02 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 668
Exercise price: $0.000000
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The stock options were granted under the Company's 2025 Long-Term Incentive Plan and generally vest 100% after a one year period.

Footnote F2

Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period with the RSU vesting immediately upon termination of the Director's service.